Allergan Inc. - Articles and news items

Novartis enter agreement with Conatus for NASH treatment

Industry news / 10 May 2017 / Niamh Marriott, Junior Editor

This follows the initiation of the Phase IIb trial by Conatus evaluating emricasan in patients with decompensated liver cirrhosis caused by NASH…

Aptar Pharma & Kali Care to develop medication monitoring tech for trials

Industry news / 8 May 2017 / Niamh Marriott, Junior Editor

Aptar Pharma’s dispensing technologies combined with Kali Care’s smart sensors, data analytics and cloud services will make clinical trials more efficient.

Allergan partners with TARGET PharmaSolutions to advance NASH research

Industry news / 21 April 2017 / Niamh Marriott, Junior Editor

Allergan will collaborate with TARGET PharmaSolutions, a clinical data company focused on real world evidence, on its TARGET-NASH study.

Novartis expands development programs for NASH with Allergan clinical partnership

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

FDA clearance for Allergan’s refractory glaucoma treatment

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

The XEN Glaucoma Treatment System reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas…

Allergan acquires Motus following positive diabetic gastroparesis trial

Industry news / 28 October 2016 / Niamh Louise Marriott, Digital Content Producer

Results of a Phase 2b trial of relamorelin, Motus’ ghrelin agonist, for the treatment of gastroparesis in diabetics has led to Allergan acquiring Motus…

MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

Allergen receives positive opinion for IBS drug

Industry news / 26 July 2016 / Niamh Louise Marriott, Digital Content Producer

Trubberzi is an oral medication taken to relieve the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults…

FDA approves expanded label for Namzaric in Alzheimer’s disease

Industry news / 20 July 2016 / Victoria White, Digital Content Producer

Namzaric is a fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor…

FDA approves Allergan’s hypertension drug Byvalson

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US…

Allergan and Medicines360 donate IUDs in response to Puerto Rico Zika outbreak

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

Allergan and Medicines360 are to donate 10,000 units of Liletta to the CDC Foundation in response to the Zika virus outbreak in Puerto Rico…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+